Sanofi sues US company over diabetes drug patent rights

French drugmaker Sanofi said it is suing a US pharmaceuticals company for allegedly infringing the patent on its key insulin treatment as sales of its diabetes drugs are falling.

Sanofi's Lantus insulin , a major source of revenue for the French group, is no longer being reimbursed by several top US which have switched to a cheaper competitor.

That pushed sales of the French group's diabetes treatments down by 12 percent in the second quarter.

Sanofi said in a statement late Tuesday that it is suing US-based Mylan for alleged infringement of 18 patents covering the Lantus and the insulin pen SoloStar.

The suit was triggered after Mylan filed a new drug application with the US Food and Drug Administration (FDA) for insulin glargine pre-filled pen and vial drug products, Sanofi said.

Sanofi has already filed two similar patent infringement suits concerning Lantus against US drug giant Merck.

And in 2014, Sanofi also took another US company Eli Lilly over Lantus but the two sides reached an amicable settlement.

© 2017 AFP

Citation: Sanofi sues US company over diabetes drug patent rights (2017, October 25) retrieved 17 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Sanofi sues Eli Lilly for patent infringement


Feedback to editors